LAUSR

column, eluting with CHCl3–MeOH (3:2) to provide four major fractions (B1–B4). Compounds 1 (56 mg) and 6 (915 mg) were obtained from Fr. B1 (1.5 g) on a silica gel column, eluting with petroleum ether–EtOAc (10:1), and then purified on Sephadex LH-20 with CHCl3–MeOH (3:2). Fraction B2 (1.0 g) was purified on a silica gel column (CHCl3–MeOH, 100:1) and then isolated on Sephadex LH-20 with CHCl3–MeOH (3:2) to furnish 15 (17 mg). Compound 10 (15 mg) was obtained from Fr. B3 (54 mg) on silica gel with CHCl3–acetone (50:1) and further purified on Sephadex LH-20, eluting with CHCl3–MeOH (3:2). Fraction B4 (55 mg) was subjected to silica gel column chromatography, eluting with petroleum ether–EtOAc (5:1), and then fractionated on Sephadex LH-20 with CHCl3–MeOH (3:2) to give 7 (8 mg). Fraction 4 (4.9 g) was submitted to a Sephadex LH-20 column eluting with CHCl3–MeOH (3:2) to give four fractions (C1–C4). Compound 11 (4 mg) was obtained from Fr. C1 (89 mg) on a silica gel column, eluting with petroleum ether–EtOAc (5:1), and purified on a Sephadex LH-20 column with CHCl3–MeOH (3:2). Fraction C2 (120 mg) was separated on a silica gel column with CHCl3–acetone (50:1) to yield 3 (70 mg). Compounds 2 (6 mg) and 4 (18 mg) were obtained from Fr. C3 (128 mg) by silica gel chromatography with CHCl3–acetone (50:1) and further purified on Sephadex LH-20 with CHCl3–MeOH (3:2). Compound 5 (6 mg) was obtained from Fr. C4 (89 mg) on a silica gel column, eluting with petroleum ether–EtOAc (5:1), and then purified on Sephadex LH-20 with CHCl3–MeOH (3:2). Fraction 5 (11.4 g) was applied to a Sephadex LH-20 column with CHCl3–MeOH (3:2) to provide four major fractions (D1–D4). Compound 12 (15 mg) was obtained from Fr. D1 (1.2 g) on a silica gel column, eluting with petroleum ether–EtOAc (2:1), and then purified on Sephadex LH-20 with CHCl3–MeOH (3:2). Fraction D2 (1.5 g) was purified on a silica gel column (petroleum ether–EtOAc, 2:1) and then isolated on a Sephadex LH-20 column with